Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone484-713-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$350,000.00
Profitability
Miscellaneous
Employees19
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Fibrocell Science (NASDAQ:FCSC) Frequently Asked Questions
What is Fibrocell Science's stock symbol?
Fibrocell Science trades on the NASDAQ under the ticker symbol "FCSC."
When did Fibrocell Science's stock split? How did Fibrocell Science's stock split work?
Shares of Fibrocell Science reverse split on the morning of Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of Fibrocell Science stock prior to the reverse split would have 20 shares after the split.
How were Fibrocell Science's earnings last quarter?
Fibrocell Science Inc (NASDAQ:FCSC) issued its quarterly earnings data on Wednesday, August, 14th. The company reported $1.12 EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $1.30. The firm had revenue of $21.79 million for the quarter. View Fibrocell Science's Earnings History.
When is Fibrocell Science's next earnings date?
What price target have analysts set for FCSC?
2 brokers have issued twelve-month target prices for Fibrocell Science's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Fibrocell Science's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price. View Analyst Price Targets for Fibrocell Science.
What is the consensus analysts' recommendation for Fibrocell Science?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fibrocell Science in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Fibrocell Science.
What are Wall Street analysts saying about Fibrocell Science stock?
Here are some recent quotes from research analysts about Fibrocell Science stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We are downgrading to Neutral and lowering our price target to $3 from $20 to reflect the valuation offered and accepted by Fibrocell’s management as part of the acquisition terms. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Further, until closing, there is no guarantee that the acquisition will close, which could then prompt us to reassess our valuation of Fibrocell." (9/13/2019)
- 2. According to Zacks Investment Research, "Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. " (8/21/2019)
Has Fibrocell Science been receiving favorable news coverage?
News articles about FCSC stock have been trending somewhat negative this week, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fibrocell Science earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Fibrocell Science.
Are investors shorting Fibrocell Science?
Fibrocell Science saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 303,200 shares, a drop of 30.0% from the August 30th total of 432,900 shares. Based on an average daily volume of 140,800 shares, the short-interest ratio is currently 2.2 days. Approximately 4.1% of the shares of the stock are short sold. View Fibrocell Science's Current Options Chain.
Who are some of Fibrocell Science's key competitors?
Some companies that are related to Fibrocell Science include Scpharmaceuticals (SCPH), IDEAYA Biosciences (IDYA), Paratek Pharmaceuticals (PRTK), OASMIA PHARMACE/ADR (OASM), Abeona Therapeutics (ABEO), Adamas Pharmaceuticals (ADMS), Fulcrum Therapeutics (FULC), Menlo Therapeutics (MNLO), Strongbridge Biopharma (SBBP), Eton Pharmaceuticals (ETON), Helix Biopharma (HBPCF), Corvus Pharmaceuticals (CRVS), Correvio Pharma (CORV), Aptinyx (APTX) and Processa Pharmaceuticals (PCSA).
What other stocks do shareholders of Fibrocell Science own?
Who are Fibrocell Science's key executives?
Fibrocell Science's management team includes the folowing people:
- Mr. John Michael Maslowski, Pres, CEO & Director (Age 44)
- Mr. Sean D. Buckley, VP of Bus. Admin. & Corp. Sec. (Age 37)
- Mr. Robert G. Partridge, VP of Global Marketing, Communications and Investor Relations
- Ms. Michele Mchugh-Mazzatta, VP of Sales
- Dr. Pierre Compte, Managing Director of Switzerland
How do I buy shares of Fibrocell Science?
Shares of FCSC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Fibrocell Science's stock price today?
One share of FCSC stock can currently be purchased for approximately $2.96.
How big of a company is Fibrocell Science?
Fibrocell Science has a market capitalization of $28.89 million and generates $350,000.00 in revenue each year. The company earns $-10,280,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Fibrocell Science employs 19 workers across the globe.View Additional Information About Fibrocell Science.
What is Fibrocell Science's official website?
How can I contact Fibrocell Science?
Fibrocell Science's mailing address is 405 EAGLEVIEW BOULEVARD, EXTON PA, 19341. The company can be reached via phone at 484-713-6000 or via email at [email protected]
MarketBeat Community Rating for Fibrocell Science (NASDAQ FCSC)
MarketBeat's community ratings are surveys of what our community members think about Fibrocell Science and other stocks. Vote "Outperform" if you believe FCSC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FCSC will underperform the S&P 500 over the long term. You may vote once every thirty days.
